A5076438320- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Renal cell carcinoma treatment
- Colorectal Cancer Treatments and Studies
- Neuroendocrine Tumor Research Advances
- Hepatocellular Carcinoma Treatment and Prognosis
- Vitamin D Research Studies
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- PARP inhibition in cancer therapy
- Genetic factors in colorectal cancer
- Lung Cancer Treatments and Mutations
- Cancer Research and Treatments
- Cancer Cells and Metastasis
- Cancer Treatment and Pharmacology
- Economic and Financial Impacts of Cancer
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Research Studies
- Pancreatitis Pathology and Treatment
- Liver Disease Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Cancer, Lipids, and Metabolism
- BRCA gene mutations in cancer
- Peptidase Inhibition and Analysis
Memorial Sloan Kettering Cancer Center
2016-2025
Cornell University
2016-2025
Kettering University
2014-2025
Alliance for Clinical Trials in Oncology
2023-2025
Weill Cornell Medicine
2017-2024
Dana-Farber Cancer Institute
2010-2024
Boston Medical Center
2024
Icahn School of Medicine at Mount Sinai
2024
Trinity College Dublin
1989-2024
Parker Institute for Cancer Immunotherapy
2022-2024
Patients with a germline BRCA1 or BRCA2 mutation make up small subgroup of those metastatic pancreatic cancer. The poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitor olaparib has had antitumor activity in this population.
Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between patients eligible resection with curative intent those unresectable disease. Systemic therapy is used in the neoadjuvant or adjuvant cancer setting, as well management of locally advanced metastatic Clinical trials are critical making progress treatment cancer. The NCCN Guidelines Pancreatic Adenocarcinoma focus on diagnosis systemic...
The combination of gemcitabine plus bevacizumab produced a 21% response rate and median survival 8.8 months in multicenter phase II trial patients with metastatic pancreatic cancer. These encouraging data led Cancer Leukemia Group B (CALGB) to conduct double-blind, placebo-controlled, randomized III gemcitabine/bevacizumab versus gemcitabine/placebo advanced cancer patients.
In Brief Background: Despite data suggesting a rising worldwide incidence, intrahepatic cholangiocarcinoma (IHC) remains an uncommon disease. This study analyzes changes in IHC frequency, demographics, and treatment outcome consecutive single institutional cohort. Methods: Consecutive patients with confirmed seen treated over 16-year period were included. The trend frequency the was compared that of hilar (HCCA) during same time. Demographics patient disposition, histopathologic, treatment,...
<h3>Importance</h3> Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients advanced or metastatic colorectal cancer, but the optimal choice of initial therapy in previously untreated is unknown. <h3>Objective</h3> To determine if addition cetuximab vs bevacizumab combination leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) regimen irinotecan (FOLFIRI) superior as first-line metastatic<i>KRAS</i>wild-type (wt) cancer....
Abstract Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients 1 , yet harbours mutation-derived T cell neoantigens that are suitable for vaccines 2,3 . Here a phase I trial adjuvant autogene cevumeran, an individualized neoantigen vaccine based on uridine mRNA–lipoplex nanoparticles, we synthesized mRNA real time from surgically resected PDAC tumours. After surgery, sequentially administered atezolizumab (an anti-PD-L1 immunotherapy), cevumeran (a maximum 20 per patient) and...
Purpose Patients with advanced pancreas cancer present disease that is poorly responsive to conventional therapies. Preclinical and early clinical evidence has supported targeting the epidermal growth factor receptor (EGFR) signaling pathway in patients cancer. This trial was conducted evaluate contribution of an EGFR-targeted agent standard gemcitabine therapy. Cetuximab a monoclonal antibody against ligand-binding domain receptor. Methods unresectable locally or metastatic pancreatic...
Ambulatory patients receiving systemic cancer therapy are at varying risk for venous thromboembolism. However, the benefit of thromboprophylaxis in these is uncertain.In this double-blind, randomized trial involving high-risk ambulatory with (Khorana score ≥2, on a scale from 0 to 6, higher scores indicating thromboembolism), we randomly assigned without deep-vein thrombosis screening receive rivaroxaban (at dose 10 mg) or placebo daily up 180 days, every 8 weeks. The primary efficacy end...
New therapeutic options for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) are needed. This study evaluated dual checkpoint combination therapy in mPDAC.To evaluate the safety and efficacy of anti-PD-L1 (programmed death-ligand 1) antibody using either durvalumab monotherapy or anticytotoxic T-lymphocyte antigen 4 plus tremelimumab mPDAC.Part A this multicenter, 2-part, phase 2 randomized clinical trial was a lead-in safety, open-label planned expansion to part B pending...
Microsatellite instability (MSI) and/or mismatch repair deficiency (MMR-D) testing has traditionally been performed in patients with colorectal (CRC) and endometrial cancer (EC) to screen for Lynch syndrome (LS)-associated predisposition. The recent success of immunotherapy high-frequency MSI (MSI-H) MMR-D tumors now supports all advanced solid tumors. extent which LS accounts MSI-H across heterogeneous tumor types is unknown. Here, we establish the prevalence according status.MSI status was...
BACKGROUND This phase 2 multi‐institutional study was designed to determine whether gemcitabine (GEM) with fractionated stereotactic body radiotherapy (SBRT) results in acceptable late grade 4 gastrointestinal toxicity when compared a prior trial of GEM single‐fraction SBRT patients locally advanced pancreatic cancer (LAPC). METHODS A total 49 LAPC received up 3 doses (1000 mg/m ) followed by 1‐week break and (33.0 gray [Gy] 5 fractions). After SBRT, continued receive until disease...
Purpose: Various genetic driver aberrations have been identified among distinct anatomic and clinical subtypes of intrahepatic extrahepatic cholangiocarcinoma, these molecular alterations may be prognostic biomarkers and/or predictive drug response.Experimental Design: Tumor samples from patients with cholangiocarcinoma who consented prospectively were analyzed using the MSK-IMPACT platform, a targeted next-generation sequencing assay that analyzes all exons selected introns 410...
<h3>Importance</h3> Guidelines for cancer genetic testing based on family history may miss clinically actionable changes with established implications screening or prevention. <h3>Objective</h3> To determine the proportion and potential clinical of inherited variants detected using simultaneous sequencing tumor normal tissue ("tumor-normal sequencing") compared test results current guidelines. <h3>Design, Setting, Participants</h3> From January 2014 until May 2016 at Memorial Sloan Kettering...
The incidence of gallbladder cancer (GBC) in the US is 1.2/100,000. This report examines patterns presentation, adjuvant treatment and survival a large cohort patients with GBC evaluated at MSKCC over 10-year period.A retrospective analysis referred to diagnosis between January 1995 December 2005 was performed. Patients were identified from registry. Information extracted included, demographics, clinical pathological stage, surgical management, pathology, palliative therapy, date relapse,...
Purpose Bevacizumab improves survival in several solid tumor malignancies when combined with chemotherapy. We evaluated the efficacy and safety of addition bevacizumab to chemotherapy treatment gastric gastroesophageal junction (GEJ) adenocarcinoma. Patients Methods Forty-seven patients metastatic or unresectable gastric/GEJ adenocarcinoma were treated 15 mg/kg on day 1, irinotecan 65 mg/m 2 , cisplatin 30 days 1 8, every 21 days. The primary end point was demonstrate a 50% improvement time...
BACKGROUND Angiosarcomas are rare tumors. Based on a complete response observed in patient with angiosarcoma of the scalp treated paclitaxel Phase II trial, authors cohort patients or face as single agent. METHODS The identified nine at Memorial Sloan-Kettering Cancer Center between January 1992 and December 1998. Various schedules were used over 1, 3, 24 hours. RESULTS Of 9 patients, 8 had major responses (4 partial 4 clinical responses) 1 minor response, for rate 89%. median duration was 5...
The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas exocrine pancreas are intended to assist with clinical decision-making. These Insights important updates 2019 version guidelines, focusing on postoperative adjuvant treatment patients pancreatic cancers.
Abstract Purpose: Immune checkpoint inhibition has been shown to generate profound and durable responses in mismatch repair deficient (MMR-D) solid tumors elicited interest detection tools strategies guide therapeutic decision-making. Herein we address questions on the appropriate screening, methods, patient selection, initiation of therapy for MMR-D pancreatic ductal adenocarcinoma (PDAC) assess utility next-generation sequencing (NGS) providing additional prognostic predictive information...
The purpose of cancer staging systems is to accurately predict patient prognosis. outcome advanced hepatocellular carcinoma (HCC) depends on both the stage and extent liver dysfunction. Many that include aspects have been developed. It remains unknown, however, which these optimal for predicting survival.Patients with HCC treated over a 5-year period at Memorial Sloan-Kettering Cancer Center were identified from an electronic medical record database. Patients sufficient data utilization in...
Appendiceal tumors exhibiting both neuroendocrine and glandular differentiation are uncommon have caused difficulty in pathologic classification, prediction of prognosis, clinical management. Previously, such lesions been variously designated as adenocarcinoid, goblet cell carcinoid (GCC), mixed adenocarcinoma carcinoid. In this study, we undertook a retrospective investigation 63 cases classified them typical GCC (group A) ex on the basis histologic features tumor at primary site. The group...
3504 Background: 80405 found no OS or PFS difference when Bevacizumab (BV) Cetuximab (Cet) was added to 1st-line FOLFOX FOLFIRI in mCRC pts. As location of the 1° may affect outcome, we assessed impact side (R v L) on and Methods: determined by chart review: 1137 pts w/KRAS wt (codons 12 13) main cohort; 252 w/ KRAS mut tumors treated BV Cet pre-amendment. R-sided = cecum hepatic flexure; L-sided splenic flexure rectum. Transverse (T) flexure. per investigator. Kaplan Meier Cox regression...